Literature DB >> 2303014

Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin.

P C Van Ness1.   

Abstract

Seven patients with complex partial or secondarily generalized tonic-clonic status epilepticus (SE) refractory to benzodiazepines (BZDs) and phenytoin (PHT) were treated with pentobarbital (PTB) coma with an EEG burst suppression (BSP) pattern. PTB administered by continuous intravenous (i.v.) infusion pump at a loading dose of 6-8 mg/kg in 40-60 min was usually sufficient to produce BSP activity and seizure control. PTB was continued 0-24 h at 1-4 mg/kg/h, adjusted to maintain blood pressure (BP) and BSP. Infusion rate was decreased if systolic BP (SBP) was less than 90 mm Hg. Normal saline fluid challenge was occasionally used to elevate BP, but in no case was it necessary to discontinue PTB infusion or use pressors. Other antiepileptic drugs (AEDs) were maintained at therapeutic levels for chronic seizure protection. Seizures were stopped in all cases. Four patients attained premorbid neurologic status, two patients briefly survived in vegetative states with recurring seizures after PTB withdrawal, and one patient died of asystole after receiving PTB for 7 h. Patients who had poor outcomes had prolonged seizures (16 h to 3 weeks) before institution of PTB anesthesia, and all had significant underlying central nervous system (CNS) pathology. PTB-induced BSP appears to be safe and effective for refractory SE if it is started soon after failure of a BZD and PHT. Ultimate prognosis depends on SE etiology.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303014     DOI: 10.1111/j.1528-1157.1990.tb05361.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  19 in total

1.  Convulsive Status Epilepticus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

2.  Diagnosis and Treatment of Nonconvulsive Status Epilepticus in an Intensive Care Unit Setting.

Authors:  Stephan J. Rüegg; Marc A. Dichter
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

3.  Spectral Content of Electroencephalographic Burst-Suppression Patterns May Reflect Neuronal Recovery in Comatose Post-Cardiac Arrest Patients.

Authors:  Krithiga Sekar; Nicholas D Schiff; Douglas Labar; Peter B Forgacs
Journal:  J Clin Neurophysiol       Date:  2019-03       Impact factor: 2.177

Review 4.  Generalized convulsive status epilepticus: pathophysiology and treatment.

Authors:  F B Scholtes; W O Renier; H Meinardi
Journal:  Pharm World Sci       Date:  1993-02-19

5.  Acute Resective Surgery for the Treatment of Refractory Status Epilepticus.

Authors:  Maysaa Merhi Basha; Kushak Suchdev; Monica Dhakar; William J Kupsky; Sandeep Mittal; Aashit K Shah
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

6.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

Review 7.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

8.  Observed medical and surgical complications of prolonged barbiturate coma for refractory status epilepticus.

Authors:  Christopher R Newey; Dolora Wisco; Premkumar Nattanmai; Aarti Sarwal
Journal:  Ther Adv Drug Saf       Date:  2016-07-18

9.  Bowel ischemia: a rare complication of thiopental treatment for status epilepticus.

Authors:  Carlo Cereda; Mette M Berger; Andrea O Rossetti
Journal:  Neurocrit Care       Date:  2008-11-25       Impact factor: 3.210

Review 10.  Status epilepticus. Clinical features, pathophysiology, and treatment.

Authors:  C Watson
Journal:  West J Med       Date:  1991-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.